↓ Skip to main content

Dove Medical Press

Article Metrics

Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, February 2016
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
57 Mendeley
Title
Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations
Published in
International Journal of Chronic Obstructive Pulmonary Disease, February 2016
DOI 10.2147/copd.s93303
Pubmed ID
Authors

Clair Clowes, Dirkje Postma, Antonio Anzueto, Barry Make, Goran Eriksson, Stefan Peterson, Christine Jenkins, Peter MA Calverley

Abstract

Early treatment response markers, for example, improvement in forced expiratory volume in 1 second (FEV1) and St George's Respiratory Questionnaire (SGRQ) total score, may help clinicians to better manage patients with chronic obstructive pulmonary disease (COPD). We investigated the prevalence of clinically important improvements in FEV1 and SGRQ scores after 2-month budesonide/formoterol or formoterol treatment and whether such improvements predict subsequent improvements and exacerbation rates. This post hoc analysis is based on data from three double-blind, randomized studies in patients with moderate-to-very-severe COPD receiving twice-daily budesonide/formoterol or formoterol alone for 6 or 12 months. Prebronchodilator FEV1 and SGRQ total score were measured before treatment and at 2 and 12 months; COPD exacerbation rates were measured during months 2-12. Responders were defined by ≥100 mL improvement in prebronchodilator FEV1 and ≥4-point decrease in SGRQ total score. Overall, 2,331 and 1,799 patients were included in the 0-2- and 0-12-month responder analyses, respectively, and 2,360 patients in the 2-12-month exacerbation rate analysis. At 2 months, 35.1% of patients were FEV1 responders and 44.3% were SGRQ responders. The probability of response was significantly greater with budesonide/formoterol than with formoterol or placebo for both parameters. Two-month responders had a greater chance of 12-month response than 2-month nonresponders for both FEV1 (odds ratio, 5.57; 95% confidence interval, 4.14-7.50) and SGRQ (odds ratio, 3.87; 95% confidence interval, 2.83-5.31). Two-month response in FEV1 (P<0.001), but not SGRQ (P=0.11), was associated with greater reductions in exacerbation risk. Early FEV1 and SGRQ treatment responses relate to their changes at 12 months. FEV1 response, but not SGRQ response, at 2 months predicts the risk of a future COPD exacerbation in some, but not all patients. This is potentially useful in clinical practice, although more sensitive and specific markers of favorable treatment response are required.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Spain 1 2%
South Africa 1 2%
Brazil 1 2%
Unknown 53 93%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 12 21%
Other 8 14%
Researcher 8 14%
Student > Master 6 11%
Student > Ph. D. Student 5 9%
Other 11 19%
Unknown 7 12%
Readers by discipline Count As %
Medicine and Dentistry 28 49%
Pharmacology, Toxicology and Pharmaceutical Science 6 11%
Nursing and Health Professions 4 7%
Psychology 3 5%
Economics, Econometrics and Finance 2 4%
Other 5 9%
Unknown 9 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 February 2016.
All research outputs
#5,495,802
of 7,282,696 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#677
of 905 outputs
Outputs of similar age
#197,961
of 282,407 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#57
of 68 outputs
Altmetric has tracked 7,282,696 research outputs across all sources so far. This one is in the 13th percentile – i.e., 13% of other outputs scored the same or lower than it.
So far Altmetric has tracked 905 research outputs from this source. They receive a mean Attention Score of 4.2. This one is in the 6th percentile – i.e., 6% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 282,407 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 68 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.